- Meeting abstract
- Open Access
EHMTI-0293. Comparison between celecoxib and prednisolone in bridge stage therapy following medication overuse headache: double blind randomized clinical trial
The Journal of Headache and Pain volume 15, Article number: C54 (2014)
Many patients with chronic or frequent headaches overuse the analgestic or anti-migraine drugs. Medication overuse headache (MOH) is a common severe headache. The basis of treatment of MOH is discontinuation of the offending drugs. However, cessation of drug consumption could lead to severe disabling headache. Corticosteroids are the most popular drugs for bridge phase of treatment. However corticosteroids might cause different side effects. Celecoxib is a Cox 2 inhibitor drug with analgesic and anti-inflammatory properties, assumed to be a good alternative for steroids.
We conducted this study to compare celecoxib with prednisolone for bridge stage therapy in MOH.
103 patients (18-65 years) with at least 15 days of headache per month were enrolled. They assigned into two groups: celecoxib (53 cases) and prednisolone (51 cases). Prednisone was administered as daily doses of 75, 50, 30, 25, and 10 mg in 3 days interval. Celecoxib was administered for 15 days according to the following schedule: 100 mg three times per day (5 days), twice a day (5 days) and once a day (5 days). The severity and duration of headache, as well as side effects were assessed.
No significant differences were observed in the decrement of the severity and duration (p=0.114 and 0.149 respectively) of headache between two groups. Side effects were reported in 42 % and 18.9% of prednisolone and celcoxibe groups respectively (Relative Risk=2.2, p=0.011).
Celecoxib has similar efficacy and fewer side compared to prednisolone during withdrawal therapy.
No conflict of interest.
About this article
Cite this article
Togha, M., Paknejad, S., Taghvaei, E. et al. EHMTI-0293. Comparison between celecoxib and prednisolone in bridge stage therapy following medication overuse headache: double blind randomized clinical trial. J Headache Pain 15, C54 (2014). https://doi.org/10.1186/1129-2377-15-S1-C54
- Relative Risk